Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside
Authors:
Open Access
- 1 July 2009
- journal article
- review article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 15 (7) , 602-612
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice AnymoreClinical Infectious Diseases, 2007
- Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical ImpactThe Journal of Infectious Diseases, 2005
- Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated CandidiasisAntimicrobial Agents and Chemotherapy, 2004
- Attributable Mortality of Nosocomial Candidemia, RevisitedClinical Infectious Diseases, 2003
- In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2003
- In Vivo Pharmacodynamics of a New Triazole, Ravuconazole, in a Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2003
- In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2003
- Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus InfectionAntimicrobial Agents and Chemotherapy, 2001
- Aspergillosis Case-Fatality Rate: Systematic Review of the LiteratureClinical Infectious Diseases, 2001
- Lysis—centrifugation blood cultures in the detection of tissue-proven invasive candidiasis disseminated versus single-organ infectionDiagnostic Microbiology and Infectious Disease, 1993